抑郁的躯体症状与认知情感症状分别与炎症和胰岛素抵抗的不同关联:GRADE研究中情绪困扰子研究横断面与纵向结果
本研究基于GRADE试验情绪困扰子研究的二次分析,在2型糖尿病患者中评估抑郁症状(PHQ-8总分及躯体、认知情感症状簇)与胰岛素抵抗(HOMA-IR)和炎症(hsCRP)的横断面及纵向关联。结果显示,PHQ-8总分与HOMA-IR横断面正相关(0.8%,p=0.007),躯体症状评分与HOMA-IR横断面正相关(5.8%,p=0.004);纵向分析中,PHQ-8总分与hsCRP随时间正相关(0.8%,p=0.014),躯体症状簇与hsCRP纵向正相关(5.2%,p=0.017),认知情感症状均无显著关联。
要点
- PHQ-8总分每增加1分与HOMA-IR横断面升高0.8%显著相关(p=0.007)。
- 躯体症状评分与HOMA-IR横断面升高5.8%显著相关(p=0.004)。
- 纵向分析中,PHQ-8总分每增加1分与hsCRP随时间升高0.8%显著相关(p=0.014)。
核心结论
- 在2型糖尿病患者中,抑郁症状与炎症和胰岛素抵抗标志物存在横断面和纵向关联,躯体症状似乎是这些关联的驱动因素,疲劳和食欲问题可能发挥作用。
研究设计与样本
- 本研究为GRADE试验情绪困扰子研究的二次分析,纳入分析胰岛素抵抗(HOMA-IR)的参与者1321例,分析炎症(hsCRP)的参与者1739例。
- HOMA-IR在基线和第1年、第3年研究访视时评估;hsCRP在基线和每6个月评估一次,随访长达3年。
- 抑郁症状在基线使用患者健康问卷(PHQ-8)评估,计算总分及认知情感和躯体症状簇评分。
- 横断面分析采用线性回归,以基线的炎症和胰岛素抵抗为因变量;纵向分析采用线性混合效应回归,以各时间点的炎症和胰岛素抵抗为因变量。
- 所有分析中抑郁症状(总分和症状簇评分)为自变量,并控制了重要的人口学、人体测量学和代谢混杂因素。
主要发现
- 横断面分析中,调整潜在混杂因素后,PHQ-8总分每增加1分与HOMA-IR升高0.8%显著相关(p=0.007),但与hsCRP无显著关联(升高0.6%,p=0.283)。
- 躯体症状评分与HOMA-IR升高5.8%显著相关(p=0.004);单项分析显示疲劳(升高3.6%,p=0.002)和食欲增加/减少(升高3.5%,p=0.009)与HOMA-IR横断面显著相关。
- 认知情感症状评分与基线HOMA-IR无显著关联。
- 纵向分析中,PHQ-8总分每增加1分与hsCRP随时间升高0.8%显著相关(p=0.014),但与HOMA-IR随时间无显著关联(降低0.1%,p=0.564)。
- 纵向分析中,仅躯体症状簇与hsCRP随时间显著相关(升高5.2%,p=0.017),认知情感症状评分无显著关联。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Insulin resistance and inflammation are components of a biological framework that is hypothesised to be shared by type 2 diabetes and depression. However, depressive symptoms include a large heterogeneity of somatic and cognitive-affective symptoms, and this may obscure the associations within this biological framework. Cross-sectional and longitudinal data were used to disentangle the contributions of insulin resistance and inflammation to somatic and cognitive-affective symptoms of depression. METHODS: This secondary analysis used data from the Emotional Distress Sub-Study of the GRADE trial. Insulin resistance and inflammation were assessed using the HOMA-IR estimation and high-sensitivity C-reactive protein (hsCRP) levels, respectively, at baseline and at the study visits at year 1 and year 3 (HOMA-IR) and every 6 months (hsCRP) for up to 3 years of follow-up. Depressive symptoms were assessed at baseline using the Patient Health Questionnaire (PHQ-8), and a total score as well as symptom cluster scores for cognitive-affective and somatic symptoms were calculated. For the cross-sectional analyses, linear regression analyses were performed, with inflammation and insulin resistance at baseline as dependent variables. For the longitudinal analyses, linear mixed-effect regression analyses were performed, with inflammation and insulin resistance at the various time points as dependent variables. In all analyses, depressive symptoms (total score and symptom cluster scores) were the independent variables, controlled for important demographic, anthropometric and metabolic confounders. For the analysis of insulin resistance (HOMA-IR), data from 1321 participants were analysed. For the analysis of inflammation (hsCRP), data from 1739 participants were analysed. RESULTS: In cross-sectional analysis and after adjustment for potential confounders, a one-unit increase in PHQ-8 total score was significantly associated with a 0.8% increase in HOMA-IR (p=0.007), but not with hsCRP (0.6% increase, p=0.283). The somatic symptom score was associated with a 5.8% increase in HOMA-IR (p=0.004). Single-item analyses of depressive symptoms showed that fatigue (3.6% increase, p=0.002) and increased/decreased appetite (3.5% increase, p=0.009) were significantly associated with HOMA-IR cross-sectionally. The cognitive-affective symptom score was not significantly associated with HOMA-IR at baseline. In longitudinal analyses, a one-unit increase in PHQ-8 total score was significantly associated with a 0.8% increase in hsCRP over time (p=0.014), but not with HOMA-IR over time (0.1% decrease, p=0.564). Again, only the somatic symptom cluster was significantly associated with hsCRP over time (5.2% increase, p=0.017), while the cognitive-affective symptom score was not. CONCLUSION/INTERPRETATION: The results highlight the associations of depressive symptoms with markers of inflammation and insulin resistance, both cross-sectionally and longitudinally, in individuals with type 2 diabetes. In particular, somatic symptoms of depression appear to be the driver of these associations, even after controlling for concomitant conditions, with a potential role for fatigue and issues with appetite. TRIAL REGISTRATION: ClinicalTrials.gov NCT01794143.
引用
- Ehrmann D, Krause-Steinrauf H, Uschner D, et al. Differential associations of somatic and cognitive-affective symptoms of depression with inflammation and insulin resistance: cross-sectional and longitudinal results from the Emotional Distress Sub-Study of the GRADE study. Diabetologia. 2025. PMID: 39951058. doi:10.1007/s00125-025-06369-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。